News and research before it hits the news on CNBC and more. Claim your 1 week free trial Street Insider Premium Here.
-
Dr. Grosso will develop and execute the company’s expanding clinical trial program.
-
Tevogen’s cell therapy research pipeline focuses on virology, neurology, and oncology.
-
Tevogen is reported as the most valuable tech startup in 2022.
WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in virology, neurology and oncology, today announced the appointment of Dr. Appointed and the company’s expanding clinical trial portfolio.
This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/20230104005931/en/
Dr. Dolores Grosso, Global Head of Clinical Development, Tevogen Bio (Photo: Business Wire)
Dr. Grosso has been in healthcare for over 40 years. During his first 15 years he worked as a critical care nurse at Thomas Jefferson University in Philadelphia. He earned his Master of Science degree in 1986 and his Postmaster’s Nurse Practitioner degree in 1995, both from the University of Pennsylvania in Critical Care Nursing. In 1996, she participated in a blood and bone marrow transplant program as a nurse at Thomas Herr Jefferson University.
Over the next 25 years, Dr. Grosso expanded his career in cell therapy research under the guidance of eminent oncologist Professor Neal Flomenberg. Jefferson University. Later that year, she was appointed to the faculty of the Jefferson School of Medicine, eventually earning her the position of Associate Professor of Research in early 2022. Dr. Grosso has authored over 20 of her investigator-initiated research protocols, including multiple first and final author publications. She has served as research mentor to numerous Physician Fellows, including several participating in the Master of Pharmacology program at Jefferson University. In 2021, she will receive a prestigious clinical research award from her Thomas Kimmel Cancer Center at Jefferson University in Sydney in recognition of her prolific research work and her contributions to the cancer center’s clinical research efforts. Received the Excellence Award.
Dr Grosso said: treatment of illness. ”
“Since our founding in 2020, our advanced science and business model have made us one of the most successful start-up biotech companies. As the founder of Tevogen, Dr. Grosso’s unique experience and unwavering We are excited to welcome Passion to our leadership team.
About Tevogen’s Next Generation Precision T Cell Platform
Tevogen’s next-generation precision T-cell platform is designed to increase immunological specificity to eliminate malignant and virus-infected cells while keeping healthy cells intact. Multiple targets are selected in advance with the goal of overcoming the mutational capacity of cancer cells and viruses. Otherwise, it can escape immunological targets.
Tevogen is exploring the technology’s potential to overcome key barriers to widespread application of personalized T-cell therapy, including potency, purity, large-scale production, and patient pairing, without the limitations of current approaches . Tevogen’s goal is to open up vast and unprecedented possibilities for developing personalized immunotherapies for large patient populations affected by common cancers and viral infections.
Tevogen has announced the completion of patient enrollment in a proof-of-concept clinical trial of its lead product, TVGN-489. It is in ambulatory acute-risk COVID-19 patients with no observed dose-limiting toxicities or serious treatment-related adverse events. Any patient at any dose level.
TVGN-489 is a non-genetically engineered off-the-shelf allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple precise targets across the SARS-CoV-2 genome.
About Tevogen Bio
Tevogen Bio is driven by a team of experienced industry leaders and distinguished scientists with experience in drug development and global product launches. Tevogen management believes that accessible personalized immunotherapy is the next frontier in medicine and that disruptive business models are needed to sustain medical innovation in a post-pandemic world.
Forward-Looking Statements
This press release contains certain forward-looking statements regarding Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are based on known and unknown risks, delays and uncertainties and statements regarding actual results, performance or forward-looking statements thereof. results, performance or other results that are materially different from those implied by Forward-looking statements are defined as “may,” “will,” “should,” “intend,” “expect,” “believe,” “could,” may be identified by terms such as, or the negation or equivalent thereof. Terms and other words and expressions that refer to future events, conditions, or circumstances. Forward-looking statements in which the Company expresses expectations or beliefs regarding future results do not provide any assurance that those statements, expectations or beliefs will be achieved. Various factors may cause differences between our forecasts and actual results. For example: Uncertainties inherent in the conduct, costs and completion of preclinical and clinical trials. risks associated with regulatory review, approval and commercial development; Risks Associated with Intellectual Property Protection. risks associated with matters that may affect our future financial results, including the commercial potential, sales and pricing of our products; We undertake no obligation to update any forward-looking statements or information in this release, or to provide additional information, except as required by law and expressly disclaims all liability and We make no representations or warranties in connection with the release. I respect the omission from there.
View source version at businesswire.com: https://www.businesswire.com/news/home/20230104005931/en/
Tevogen Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]
Source: Tevogen Bio
